Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Johnson & Johnson
Deal Size : $78.0 million
Deal Type : Series B Financing
Perceive Biotherapeutics Attracts $78M Series B Financing to Advance Diversified Pipeline
Details : The net proceeds from the funding will be used to fuel Perceive Biotherapeutics progress as it drives lead AMD program into the clinic and continues development progress across extensive ophthalmology pipeline.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Johnson & Johnson
Deal Size : $78.0 million
Deal Type : Series B Financing
Reset All
